- Home
- PYPD vs ITRM Comparison
PYPD vs ITRM Comparison
Compare PYPD & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- ITRM
- Stock Information
- Founded
- PYPD 2008
- ITRM 2015
- Country
- PYPD Israel
- ITRM Ireland
- Employees
- PYPD N/A
- ITRM N/A
- Industry
- PYPD Medical/Dental Instruments
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- ITRM Health Care
- Exchange
- PYPD Nasdaq
- ITRM Nasdaq
- Market Cap
- PYPD 35.3M
- ITRM 40.0M
- IPO Year
- PYPD 2020
- ITRM 2018
- Fundamental
- Price
- PYPD $3.44
- ITRM $0.98
- Analyst Decision
- PYPD Strong Buy
- ITRM Strong Buy
- Analyst Count
- PYPD 5
- ITRM 2
- Target Price
- PYPD $11.40
- ITRM $7.00
- AVG Volume (30 Days)
- PYPD 1.4M
- ITRM 478.2K
- Earning Date
- PYPD 08-13-2025
- ITRM 08-13-2025
- Dividend Yield
- PYPD N/A
- ITRM N/A
- EPS Growth
- PYPD N/A
- ITRM N/A
- EPS
- PYPD N/A
- ITRM N/A
- Revenue
- PYPD N/A
- ITRM N/A
- Revenue This Year
- PYPD N/A
- ITRM N/A
- Revenue Next Year
- PYPD N/A
- ITRM $270.19
- P/E Ratio
- PYPD N/A
- ITRM N/A
- Revenue Growth
- PYPD N/A
- ITRM N/A
- 52 Week Low
- PYPD $2.30
- ITRM $0.81
- 52 Week High
- PYPD $4.49
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- PYPD 56.85
- ITRM 45.38
- Support Level
- PYPD $3.45
- ITRM $0.93
- Resistance Level
- PYPD $3.62
- ITRM $1.03
- Average True Range (ATR)
- PYPD 0.20
- ITRM 0.05
- MACD
- PYPD -0.01
- ITRM 0.00
- Stochastic Oscillator
- PYPD 63.57
- ITRM 17.48
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.